True Leaf Medicine International Inc.
True Leaf Medicine International Inc.
- ISIN: CA89785C1077
- Land: .
Nachricht vom 12.10.2017 | 13:00
True Leaf Engages Boustead Securities to Underwrite Regulation A+ Offering
DGAP-News: True Leaf Medicine International Inc. / Key word(s): Miscellaneous
Vancouver, British Columbia--(Newsfile Corp. - October 12, 2017) - True Leaf Medicine International Ltd. (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF) ('True Leaf'), a company involved in the hemp and cannabis-based product industry, has filed a preliminary offering circular with the Securities and Exchange Commission ('SEC') pursuant to the Regulation A framework, which is open to both accredited and unaccredited investors.
True Leaf has engaged Boustead Securities, LLC Member: FINRA/SIPC ('Boustead'), as lead underwriter. 'Boustead looks forward to working with True Leaf's team to bring their Regulation A+ offering to investors,' commented David Dobkin of Boustead.
'We are pleased to have Boustead leading the effort,' said True Leaf CEO Darcy Bomford, 'their expertise in Regulation A has proven successful in the past.'
The purpose of the filing is to issue new shares of common stock to raise gross proceeds of up to $10 million CAD to help grow the True Leaf Pet division, and to advance the efforts of the True Leaf Medicine division with the goal of becoming a licensed producer of medicinal cannabis in Canada. Once its Regulation A+ offering has been qualified by the SEC, the offering will be made available to the general public to invest in True Leaf.
About True Leaf
True Leaf Medicine International Ltd., through its wholly owned subsidiary 'True Leaf Pet', has entered the global pet industry, forecast to reach $117 billion US in 20211, with a line of hemp-focused pet supplements in Canada, the United States and Europe. The company has also filed an application under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) to become a Canadian licensed producer of medical cannabis through its 'True Leaf Medicine' subsidiary. It has passed through the preliminary and enhanced screening process of Health Canada's review and has recently received approval to build its facility.
About Boustead Securities, LLC Member: FINRA/SIPC
Boustead Securities, LLC is an investment banking firm that advises clients on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions. Our core value proposition is our ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services. For more information, visit www.boustead1828.com.
An offering statement regarding this offering has been filed with the SEC. Once the SEC has qualified the offering statement True Leaf Medicine International Ltd. may make sales of the securities described by the offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a preliminary copy of the offering circular that is part of that offering statement HERE. You should read the offering circular before making any investment.
This news release contains forward-looking statements and management may make additional forward-looking statements in response to your questions. Such written and oral disclosures are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Although we believe our expectations expressed in such forward-looking statements are reasonable, we cannot assure you that they will be realized. Investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the anticipated results, and therefore we refer you to a more detailed discussion of the risks and uncertainties in the Company's filings with the Securities and Exchange Commission when available. The forward-looking statements contained in this news release are made only as of today, and True Leaf Medicine International Ltd. is under no obligation to revise or update these forward-looking statements.
Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/29635
|Company:||True Leaf Medicine International Inc.|
|End of News||DGAP News Service|
GBC im Fokus
Kursziel 2,10 €: Profiteur der steigenden Nachfrage nach Smartphones
UniDevice AG nutzt die weltweit unterschiedlichen Preisniveaus und die unterschiedliche Verfügbarkeit von elektronischen Geräten (hauptsächlich Smartphones) aus. Diesbezüglich hat die Gesellschaft ein internationales Netzwerk an Distributoren und Kunden für sich gewonnen. Für die kommenden Jahre rechnen wir mit einem Anstieg der Erlöse auf über 400 Mio. € (2020e) und einen Anstieg des EBIT auf bis zu 3 Mio. € (2020e). Wir haben ein Kursziel in Höhe von 2,10 € ermittelt. Das Rating lautet KAUFEN.
Der AKTIONÄR News
22. März 16:00 Hella: Das sagen die Analysten
22. März 15:58 4SC: Finanzierung steht bis 2020 – wichtige News noch 2018
Investor & Analyst Call Annual Report 2017
22. März 2018
Original-Research: Ringmetall AG (von Montega AG): Kaufen
22. März 2018